Lineage Cell Therapeutics, Inc. Construction in Progress Expenditures Incurred but Not yet Paid
Lineage Cell Therapeutics, Inc. (LCTX) reported Construction in Progress Expenditures Incurred but Not yet Paid of $455.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid · last filed 2020-03-12
- Lineage Cell Therapeutics, Inc. construction in progress expenditures incurred but not yet paid for fiscal 2018 was $455.00K.
- Lineage Cell Therapeutics, Inc. construction in progress expenditures incurred but not yet paid for fiscal 2015 was $524.00K, a 181.72% increase from fiscal 2014.
- Lineage Cell Therapeutics, Inc. construction in progress expenditures incurred but not yet paid for fiscal 2014 was $186.00K.
- Lineage Cell Therapeutics, Inc. construction in progress expenditures incurred but not yet paid for fiscal 2013 was $0.00.
| Period end | Construction in Progress Expenditures Incurred but Not yet Paid 12 month | Construction in Progress Expenditures Incurred but Not yet Paid 12 month as first filed |
|---|---|---|
| 2018-12-31 | $455.00K 10-K · filed 2020-03-12 | |
| 2015-12-31 | $524.00K 10-K · filed 2018-03-15 | |
| 2014-12-31 | $186.00K 10-K · filed 2017-03-16 | $186.73K 10-K · filed 2015-03-11 |
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 | |
| 2012-12-31 | $0.00 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |